Managed Care

Bivalirudin, Cangrelor, and Stent Thombosis: New Trials Raise More Questions

C. Michael Gibson, MS, MD, of Harvard Medical School, discusses important aspects of the HORIZONS-AMI and EUROMAX trials and tackles the question of whether a longer infusion of bivalirudin could lead to a reduced risk of stent thrombosis within 24 hours.


Medical Devices Summit Boston, MA February 19–20, 2015
3rd Annual Summit to Improve Adherence and Enhance Patient Engagement Philadelphia, PA March 9–10, 2015
Value-Added Solutions for Enhanced Customer Experience Philadelphia, PA March 9, 2015